Saccharomyces Boulardii IgG

Saccharomyces boulardii is a yeast. Most people meet it as a probiotic capsule sold for diarrhea and gut health. This test measures IgG antibodies in blood that bind S. boulardii. The clinical evidence behind this idea mostly comes from ASCA tests, which measure antibodies to S. cerevisiae, a closely related yeast.

So the useful read is not whether a probiotic left a trace. It is whether your immune system is reacting to Saccharomyces-type yeast targets in a pattern seen more often in Crohn's disease.

ASCA is among the oldest studied blood signals in Crohn's disease, and it tends to mark a more aggressive disease pattern. In some people it appears years before gut symptoms. That is the reason to pay attention to it. It is still an add-on clue, not a diagnosis.

What This Antibody Actually Measures

Your test measures IgG, a long-lived class of antibody, aimed at mannan. Mannan is a sugar-rich coating on the yeast cell wall. Doctors call this antibody family ASCA. The full name is anti-Saccharomyces cerevisiae antibodies.

S. boulardii is classified as Saccharomyces cerevisiae var. boulardii, so it shares many of the same cell-wall targets used in ASCA testing. But nearly all published human evidence measured serum ASCA against S. cerevisiae mannan, not this exact S. boulardii IgG assay. There is no separately validated clinical role for a distinct S. boulardii IgG test, and no guideline endorses it. Treat the evidence as close, but not assay-identical, and interpret a result as an ASCA-like clue rather than a validated stand-alone measurement.

B cells are the immune cells that make antibodies. They can make ASCA as part of a blood response to fungi that live in or pass through the gut. Some healthy people carry or repeatedly encounter Saccharomyces, yet their blood response stays low. The immune system often learns to ignore a normal yeast exposure.

ASCA targets a mannan sugar pattern that is not unique to Saccharomyces. The same oligomannose target appears on Candida albicans under certain conditions, and on some other microbes, so this is not a Candida-specific antibody. That is why diet, gut fungi, and Candida-heavy fungal shifts can all feed into the response.

You might expect more Saccharomyces in stool to mean more antibody in blood. One small healthy-donor study found the reverse: people with less Saccharomyces in stool had higher anti-Saccharomyces IgG. So this is not a stool yeast count. A high level points to an immune pattern, not proof of yeast overgrowth or a leaky gut.

Why a Positive Result Is About Immune Activity

S. boulardii is usually safe in healthy people, though rare bloodstream infections have been reported in severely ill or immunocompromised people, especially those with central lines. This antibody test does not diagnose that problem.

Antibiotic-associated diarrhea and C. difficile are conditions the probiotic has been studied for. The antibody does not diagnose them. Read a positive result as a marker of gut immune activity, not evidence that yeast is infecting you.

Crohn's Disease

The strongest clinical use of this antibody family is in Crohn's disease. Across studies, ASCA appears in about half to two-thirds of people with Crohn's, while it is much less common in healthy controls. That makes a positive result meaningful in the right setting.

On its own it is fairly good at ruling Crohn's in, but poor at ruling it out. A negative result does not clear you. How much a positive raises the odds depends on your starting risk, so an isolated positive with no symptoms and no family history means little. Serology is an adjunct because colonoscopy, biopsies, imaging, calprotectin, CRP, and symptoms do the main diagnostic work.

The level also tracks how the disease behaves. Higher ASCA levels go with disease in the small intestine and with stricturing or penetrating Crohn's, the forms that narrow the bowel or burrow through the bowel wall. People with higher levels tend to develop those complications faster.

Pediatric studies have linked ASCA IgG with more extensive disease and mucosal damage. Relapse prediction has been inconsistent, so this is not a marker to use for judging whether treatment is working week to week.

If you already have Crohn's, a strongly positive ASCA-like result supports tighter monitoring and earlier discussion of active management. It does not set treatment by itself.

A Signal That Can Precede Symptoms

In a study of healthy young adults later diagnosed with inflammatory bowel disease, ASCA was already present in some people years before Crohn's became clinical. It also runs in families: about 1 in 5 healthy relatives of people with Crohn's carry it without bowel symptoms.

A positive result in someone with a family history is worth taking seriously even when everything else looks normal. But it is still a risk flag, not a diagnosis. Most people who carry it will not go on to develop Crohn's.

The useful move is to know you carry it, watch for gut symptoms, and check active-inflammation markers if anything changes.

Beyond the Gut

Raised ASCA turns up in several conditions outside Crohn's. In Behcet's disease, ASCA IgG is associated with gut involvement, though it does not reliably separate intestinal Behcet's from Crohn's. In Parkinson's disease, one cross-sectional study found higher ASCA in newly diagnosed patients alongside shifts in gut fungi. That is early work, not a Parkinson's screening test.

In alcoholic hepatitis, higher blood ASCA was linked to worse survival and to Candida-heavy fungal dysbiosis. The antibody has also been reported in lupus, type 1 diabetes, rheumatoid arthritis, and antiphospholipid syndrome. These are associations, not proven causes, and the marker is not a screening test for any of them.

How It Compares to Calprotectin and CRP

This antibody answers a different question than the inflammation tests you may already know. Fecal calprotectin and C-reactive protein show whether inflammation is active now. This antibody points to a longer-standing immune pattern and possible disease behavior.

If the question is inflammatory bowel disease versus irritable bowel syndrome, fecal calprotectin does most of the work. In one prospective study, adding ASCA and pANCA to fecal markers improved accuracy only a little. Use them together, but don't trade one for the other.

Why One Reading Deserves Follow-Up

Unlike inflammation markers that swing week to week, ASCA status is often stable. Levels can fluctuate, and labs differ, but the positive-or-negative pattern often holds over years and may stay stable even after surgery to remove diseased bowel.

That stability cuts both ways. A single reading can capture the pattern reasonably well, but a borderline or surprising positive should be confirmed with the same method before you build decisions on it. If your lab uses a different assay from standard serum ASCA, compare results only within that lab's own method.

Because the antibody itself changes little, monthly tracking is not the point. The tracking that matters is calprotectin and CRP over time. Get a baseline for this antibody, confirm a positive, and then let active-inflammation markers do the ongoing work.

What to Do With an Unexpected Result

A positive result with chronic diarrhea, abdominal pain, weight loss, blood in stool, or anemia is a reason to move toward a full workup. Check fecal calprotectin and CRP, and use this result as support for a gastroenterology evaluation. Colonoscopy with biopsies is what actually diagnoses Crohn's.

A positive result without symptoms is a watch-and-confirm situation: repeat it, check calprotectin, and stay alert to new gut symptoms. A negative result when you have real symptoms does not clear you, because this antibody misses many cases. The pattern that warrants the most action is a positive antibody plus raised calprotectin plus symptoms.